Loading clinical trials...
Loading clinical trials...
This study aims to assess the value of combined treatment with RAD001 and erlotinib in patients with advanced Non Small Cell Lung Cancer treated only with chemotherapy as systemic therapy.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Novartis Pharmaceuticals
NCT06312137 · Non Small Cell Lung Cancer
NCT06814496 · Melanoma, Medullary Thyroid Cancer, and more
NCT05671510 · Non Small Cell Lung Cancer
NCT03340506 · Melanoma, Non Small Cell Lung Cancer, and more
NCT07222566 · Advanced Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer, and more
Novartis Investigative Site
Atlanta, Georgia
Novartis Investigative Site
Chicago, Illinois
Novartis Investigative Site
Boston, Massachusetts
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions